# SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer

> **NCT03816553** · PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 45 (actual)

## Conditions studied

- Recurrent Cervical Carcinoma
- Metastatic Cervical Cancer

## Interventions

- **DRUG:** SHR-1210
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT03816553
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-19
- **Primary completion:** 2020-04-30
- **Final completion:** 2022-08-31
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2023-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03816553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03816553, "SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03816553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*